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Abstract: Nearly one-third of the population reports new onset or acute insomnia in a given year.
Similarly, it is estimated that approximately 10% of the population endorses sleep initiation and
maintenance problems consistent with diagnostic criteria for chronic insomnia. For decades, acute and
chronic insomnia have been considered variations of the same condition or disorder, only really
differentiated in terms of chronicity of symptoms (days/weeks versus months). Whether or not acute
and chronic insomnia are part of the same phenomena is an important question, one that has yet to
be empirically evaluated. The goal of the present theoretical review was to summarize the definitions
of acute and chronic insomnia and discuss the role that hyperarousal may have in explaining how the
pathophysiology of acute and chronic insomnia is likely different (i.e., what biopsychological factors
precipitate and/or perpetuate acute insomnia, chronic insomnia, or both?).
Keywords: insomnia; hyperarousal; diagnostic criteria
1. Introduction
There are two general, but fundamental beliefs about insomnia that are critically evaluated
in this article: (1) Acute insomnia is simply a briefer form of chronic insomnia, and (2) insomnia
(regardless of its chronicity) is characterized by a state of hyperarousal. In order to address these issues,
the definitions of, and concepts related to, acute and chronic insomnia and hyperarousal are briefly
reviewed. Ultimately, it is argued that the distinction between acute and chronic insomnia needs to
be the subject of empirical investigation, especially when evaluating the role of hyperarousal in the
pathophysiology of insomnia.
2. Defining Acute and Chronic Insomnia (Just a Matter of Time?)
Acute Insomnia. Historically, acute insomnia (AI) has not been well defined or precisely
delineated in the literature, despite its having been included in multiple classification systems
since at least the late 1970s [1,2]. Part of the problem is multiple terms have been used to refer to
AI over this time frame. AI has been classified as adjustment insomnia, stress-related insomnia,
transient psychophysiological insomnia, symptomatic insomnia, sub-acute insomnia, and sub-chronic
insomnia [3–10]. Such variability in terminology has discouraged consensus building, both conceptually
and operationally. Another problem has been that the durational criteria for AI has been defined by
default; by any time period shorter than the criteria for chronic insomnia (CI). Over the years, CI
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has been variably defined as more than 1 month [11], 3 months [12], or 6 months [3], and therefore,
AI has also been variably defined as shorter than each of these duration thresholds. Still yet another
problem, one that also extends to CI, is that AI has not been defined based on quantitative criteria for
sleep continuity disturbance (illness severity viz. sleep latency, wake after sleep onset, early morning
awakenings, etc.). Finally, it should be noted that the various definitions and nosological classifications
for both AI and CI have been made on the basis of consensus opinion and not based on any empirical
derivation (e.g., how many consecutive nights must occur until it is unlikely that the insomnia will
remit?).
In recent years, the issue of “what is acute insomnia and how should it be defined?” has been the
subject of renewed interest, largely owing to the conduct of several natural history studies [10,13,14]
and the publication of one theoretical review dedicated to AI [6]. In the review, three definitions
of AI (Diagnostic and Statistical Manual of Mental Disorders [DSM], International Classification
of Sleep Disorders [ICSD], and International Classification of Diseases [ICD]) were compared and
contrasted. The central role of precipitating factors for AI was highlighted. Life stress was identified
as a/the primary precipitant for insomnia based on a review of several etiological models, and a
formal definition of AI was proffered. The definition had both qualitative and quantitative criteria,
included the delineation of sub-states, and required that a precipitating life event or stress condition
be identified. The specific definition put forward was as follows: AI is defined as sleep continuity
disturbance (i.e., difficulty initiating and/or maintaining sleep) occurring on at least 3 days per week
for anywhere between 1 week and 3 months. The more than or equal to one week duration threshold
(3-day minimum) allowed for the likely possibility of non-pathologic insomnia (i.e., insomnia as a
normal variation in sleep continuity, presumably occurring in association with less than optimal
circumstances for sleep [sleep without adequate homeostatic priming or sleep that occurs at times
outside the individual’s preferred sleep phase]). The remaining time frame (>1 week to 3 months) was
subdivided into: Acute (>3–14 days), transient (2–4 weeks), and sub-chronic insomnia (1–3 months).
It is important to note that this categorization was not empirically based on insomnia but was in line
with other mood disorders [6,12,15]. The quantitative criteria applied to the definition of AI were
those that are typically adopted for clinical research [13,16]. This rule is generally applied to typical
or average sleep latency and/or wake after sleep onset values. More specifically, individuals that
take ≥ 30 minutes to fall asleep or who are awake for periods of this magnitude during the night
are identified as having ‘difficulty initiating and/or maintaining sleep’ (insomnia of a severity that
warrants and/or can be successfully treated). While Ellis and colleagues do not, it is also possible
to apply the 30-minute rule to early morning awakenings (awakening 30 or more minutes prior to
one’s desired time to awake is deemed problematic). In addition to chronicity, frequency, and severity
criteria, it was also stipulated that an AI episode must have a clear precipitant, i.e., that the individual
must be able to identify a triggering event characterized as, “(1) any life event or train of life events that
results in a significant reduction in quality of life from the individual’s ideal and/or (2) distress at one’s
current situation” [6]. The concept that AI must be triggered by an event (a bio-behavioral reaction to
stress [perceived or real threat]) is further amplified in the closing section of the review. Here Ellis
and colleagues suggest that AI may be conceptualized as part of a larger, and non-pathological,
biopsychosocial process. That is, acute insomnia may be considered a normal part of the fight/flight
response. Evolutionarily speaking, AI likely represents a necessary override to the normal two process
regulation of sleep [17]. That is, if it is not safe to sleep, one should not sleep (regardless of the duration
of prior wakefulness and/or time of day). This concept is not new but was presaged by Spielman and
Glovinsky in the 1990s when they stated, “No matter how important sleep may be, it was adaptively
deferred when the mountain lion entered the cave” [7].
Chronic Insomnia. In contrast to AI, the literature on chronic insomnia is extensive [18,19].
As would be expected, formal definitions have been developed and adopted, though not without
revisions over the last 40 years. Historically (and as noted above), the definition of what constitutes
“chronic” has varied greatly. Presently, CI is a diagnostic category within all three of the major
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nosological systems: ICSD-3 (Chronic Insomnia Disorder [20]), ICD-11 (Chronic Insomnia [21]) and
DSM-5 (Insomnia Disorder [12]). All three classification systems include as criteria that the sleep
problem is: (1) Characterized by difficulty initiating and/or maintaining sleep; (2) associated with
significant daytime consequences, impairment, or distress; and (3) present despite adequate opportunity
for sleep. The ICSD-3 and the DSM-5 additionally specify that the sleep continuity problem must occur
with a frequency ≥ to 3 days per week and be of a duration of at least 3 months. The ICD-11 does not
specify quantitative criteria for insomnia frequency or chronicity and none of the diagnostic systems
utilize a quantitative threshold for severity (i.e., adopt the 30-minute rule that is commonly used for
clinical research [13,16]).
The changes in diagnostic criteria, especially with respect to chronicity, have made it difficult to
differentiate what constitutes AI versus CI (i.e., when does AI end and CI begin?). Assuming that AI
and CI represent different stages of a single disease process, it may be that the common dichotomization
is too simplistic and does not adequately capture the clinical course of insomnia disorder. For example,
when conducting a natural history study, we observed that not all individuals experiencing AI go on
to recover normal sleep or develop CI, some individuals develop a form of persistent poor sleep that
does not meet criteria for either AI or CI [14]. This observation has prompted some investigators to
denote a third type of insomnia as “subsyndromal insomnia”, “intermediate insomnia”, or “persistent
poor sleep” [9,13,14,22]. Finally, it should be noted that AI and CI may not represent different stages
of a single disease process; it may be that AI and CI are symptomatically similar but are distinct
clinical phenomena (e.g., occur with different frequencies and severities) with distinctly different
biological bases. For example, acute insomnia may occur in association with hypercortisolemia [23],
while chronic insomnia may occur in association with hyperorexinemia [24] or abnormally low levels
of γ-aminobutyric acid (GABA) [25].
3. Prevalence and Incidence of Acute and Chronic Insomnia
A number of epidemiological studies have been conducted over the course of the last
30 years [26–28]. Nearly all of these investigations have focused on the prevalence rate of chronic
insomnia. In general, chronic insomnia has been found to occur in 6–10% of the population [26–29].
Prevalence rates as high as 30% have been reported when: Duration of illness is not taken into account,
qualitative criteria are used for insomnia frequency, and/or when daytime impairment criteria are not
used to define “caseness” [27,28]. Data on the prevalence of AI has only recently been published [13].
Using the same criteria as outlined in the previous section, the prevalence rates of AI were 9.5%
(USA sample) and 7.9% (UK sample). Alternatively, several studies have attempted to estimate the
incidence of acute insomnia (typically defined as new onset insomnia). The first such study was
undertaken by Ford and Kamerow (1989) [26]. They reported that the incidence rate of new-onset
insomnia was 6.2% [26]. A decade later, a similar study was undertaken by Foley and colleagues [30].
They reported that the three-year incidence rate of insomnia was 15% (or an annual incidence rate of
approximately 5%). More recent studies provide convergent data suggesting that the annual incidence
of insomnia is between 7–8% for insomnia “syndrome” and up to 30% for the occurrence of “insomnia
symptoms” [10,31]. The only study to explicitly assess AI (using diagnostic criteria) reported that
the incidence rate of AI was between 31–37% (depending on whether DSM criteria with or without
additional case criteria (sleep latency or wake after sleep onset of 30 min or longer and a self-reported
increase in daytime impairment) was used) [13].
While there is a large measure of consistency among the AI studies (despite different methods,
measures, sampling rates, and time frames), the reported incident rates, for most of these studies,
were not truly the incidence of acute insomnia but rather the identification of new onset insomnia of
any duration (includes both AI and CI). Put differently, most of the incidence studies used interval
assessment strategies, where sleep continuity was profiled every one to three months [10,30,31].
This sampling rate lacks the temporal resolution needed to identify the onset and offset of short bouts
of insomnia. In order to resolve such a phenomenon, one would need to start with a proband of good
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sleepers and assess them on a daily or weekly basis. Our group recently undertook such a study [14].
Using these data, it was determined that the annual incidence of AI was 27% and that the annual
incidence rate of CI was 1.8%. Of those that developed AI, approximately 72% went on to recover
good sleep and 19% developed persistently poor sleep (i.e., these subjects did not recover good sleep
but also did not meet duration and/or severity thresholds consistent with DSM-5 Insomnia Disorder).
In sum, the population prevalence of chronic insomnia is around 10% while up to 30% of the
population experiences new onset or acute insomnia on an annual basis. Of those that experience AI,
the majority recover, a small minority develop CI, and up to 20% develop an intermediate form of
sleep continuity disturbance that does not meet criteria for either AI or CI. The existence of this third
group speaks to the need to think more dimensionally about insomnia chronicity and/or the need to
create a more pluralistic typology. While this may be done on theoretical grounds, empirically defining
what constitutes normal sleeplessness, acute insomnia, persistent poor sleep, and chronic insomnia
(and how these stages differ with respect to symptom severity and frequency) will no doubt make
clearer how these stages differ with respect to their etiology and pathophysiology.
4. Defining “Hyperarousal”
When acute, hyperarousal occurs as a triggered psychosomatic response to threat-related stimuli.
This response, also known as the “fight-or-flight response”, is characterized by the activation of
the autonomic nervous system and adrenal cortex with corresponding increases in adrenergic
and hypothalamic–pituitary–adrenal (HPA) axis activity [32,33]. The physiologic consequences
of such activation include increased heart and respiration rate, peripheral vasoconstriction, increased
perspiration, dilation of pupils, increased muscle tension, and increased glucose release via the
breakdown of glucogenic stores [34–36]. These responses allow the organism to be optimally resourced
(for a brief period of time) to fight or flee. While this type of hyperarousal is obviously adaptive,
this level of activation is not typically maintained for extended periods of time (e.g., the average
HPA axis stress response is between 45–60 minutes from start to finish [35,36]). Put differently,
most human stress systems in the body are self-regulating, which prohibits them from staying “on”
for extended periods of time [37,38]. This being the case, it has been hypothesized that a secondary
process or system exists that allows the individual to maintain an elevated state of “preparedness”
in response to longer-lasting environmental demands, if not overt threats [39–41]. This form of
“hyperarousal” may consist of a lower-level tonic activation of the fight/flight system [42,43] or the
activation of an, as of yet to be identified, alternative system. Consistent with the former point of
view, it has been found that individuals who work under chronic stressful circumstances, for example,
first responders or military service members, have been shown to exhibit higher levels of HPA and
adrenergic activation [44,45], though such activation is of significantly lower magnitude than occurs
with fight-or-flight responses [46–48].
5. Hyperarousal in the Context of Insomnia
It is practically axiomatic that insomnia is considered a hyperarousal disorder, i.e., that
sleeplessness occurs because of cognitive, and/or somatic, and/or neurophysiologic hyperarousal [49–52].
The evidence base for this belief, however, is not as large or unequivocal as one might expect. In
general, the case for hyperarousal is supported by studies of central and/or autonomic nervous
systems and endocrine system activation in patients with chronic insomnia as compared to good
sleepers. Examples of central nervous system measures include power spectral measures of high
frequency electroencephalogram (EEG) activity [51,53,54], EEG-based evoked response potential
measures [55,56], imaging measures of brain glucose or oxygen utilization [57], and/or neuroimaging
measures of GABA [25,58,59]. Examples of autonomic measures include heart rate [60], heart rate
variability [61], electrodermal activity [62], epinephrine or norepinephrine [63], core body temperature
measures [64], and/or metabolic rate measures [65]. Endocrine measures typically include blood-
and/or saliva-based measures of cortisol [66,67]. It is important to consider, however, that prior research
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on the hyperarousal theory of insomnia has mostly observed incremental increases in psychobiological
indices (e.g., evening levels in cortisol, core body temperature, glucose metabolism, etc.) in comparison
to what is “average”. For example, while prior studies have shown significantly greater MSLT scores
in patients with insomnia (suggesting a greater daytime wake drive relative to controls (i.e., greater
hyperarousal)), the mean group differences ranged from 2–5 minutes [68,69]. That is, these studies
compared differences in patients with insomnia to good sleeper controls (i.e., no insomnia history),
but not in comparison to fear states (e.g., subjects experiencing acute environmental threats). Put
differently, when differences were observed, it was unclear whether the magnitude of the differences
observed represented a level of activation that could preclude sleep or whether the observed tonic
activation simply represented one factor, of several, responsible for protracted difficulties with sleep
initiation and maintenance [70]. This distinction is important as increases above what is normal or
average may be statistically significant, but not necessarily clinically meaningful. One approach to
clarifying this issue would be to assess the “hyperarousal” of acute and chronic insomnia (across
multiple indices) and to compare such data with experimentally elicited startle or fear responses. In
this way, the scale of the arousal could be “biocalibrated” and this would allow for inferences about
when “hyperarousal” may or may not account for sleeplessness. Alternatively, another approach is to
use more naturalistic studies that estimate the level of hyperarousal required to prohibit sleep. For
example, findings from two classical studies on ship engineers during on-call periods showed that
high-stress/high-anticipation situations can disturb the subjective and objective quality of sleep [71,72].
Three additional important considerations when investigating the association between insomnia
and hyperarousal are that (1) daytime indices of hyperarousal may be unrelated to nocturnal indices
of hyperarousal (and insomnia may be about one or both), (2) the relative impact of wakefulness at
night should be taken into consideration when conceptualizing the effect of hyperarousal, and (3)
the association between insomnia and hyperarousal may vary with regard to insomnia type and/or
sub-type. With regard to diurnal/nocturnal differences, the neural or hormonal indices that are
overactive during sleep (e.g., increases in high frequency EEG activity [51,53]), suggesting a state
of hyperarousal) may be separate and distinct from those that are overactive during wakefulness
(e.g., increases in glucocorticoids [73–75]). Put differently, evidence that supports hyperarousal during
one phase (e.g., daytime) or state (e.g., wake), does not necessitate that hyperarousal also be present
during other phases/states. With regard to nocturnal wakefulness, it is unclear whether the group
differences in hyperarousal observed during sleep, such as increased EEG activity, metabolic rate,
or hormonal secretion [49,50], are related to condition (i.e., insomnia disorder) or whether they are
related to other factors. It is possible, for example, that these differences observed at night are better
explained by time spent awake, and not any insomnia-related disease process. Future work should,
therefore, account for the extent to which hyperarousal varies as a function of nocturnal wakefulness,
as compared to insomnia diagnosis. Finally, it may be the case that hyperarousal is more characteristic
of certain types (e.g., CI with objective short sleep duration phenotype [76]) or sub-types of insomnia
(initial, middle, and late insomnia [66]), and, therefore, these differences should be accounted for in
future research.
6. Hyperarousal May Apply to Acute but not Chronic Insomnia
If acute insomnia is genuinely a part of the fight/flight response (i.e., an override to the normal
two-process regulation of sleep timing, depth, and/or duration), it follows that hyperarousal is the
mechanism by which adaptive sleeplessness is ensured. That is, under unsafe conditions, sleep is
naturally inhibited. In the case of CI, while it is logical that the precipitant for sleeplessness may be the
same, it is unlikely given that fight/flight levels of hyperarousal may only be sustained for minutes
to hours. Thus, the emergent question is whether chronic hyperarousal (e.g., tonic activation of the
autonomic nervous system and adrenal cortex) is sufficient to produce sleeplessness by itself or in
combination with other factors. The concern, however, is that past research has, in most cases, assumed
this to be true. Recent research has been so focused on identifying the marker of hyperarousal in
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insomnia, its reliance on theory and making theory-driven hypotheses has wavered. That is, what
markers of hyperarousal, and in what context, are investigators evaluating and are these markers
consistent with the theoretical models regarding the etiology and pathophysiology of insomnia? Let’s
take hypercortisolemia as an example. One possible explanation for the pathophysiology of insomnia
is that CI results from excessive CNS activation [53,77–80]. The identified substrates for excessive
CNS activation have been related to catecholaminergic function and/or HPA axis dysregulation, in the
form of increased cortisol secretion [81]. Theoretically this seems plausible given what was discussed
above regarding the acute sleeplessness that naturally occurs in response to a perceived or real threat.
The scientific literature on hypercortisolemia as an index for hyperarousal in chronic insomnia is
surprisingly mixed [66,73,82–87]. The primary issue here is that the definition of hypercortisolemia
has been inconsistent across studies [67]. Like most other biological systems, the HPA axis is dynamic,
with multiple regulatory inputs [88,89], and, therefore, no two measures of HPA axis functioning (or the
resultant cortisol secretion) are the same. For example, cortisol secretion at night while one is asleep
has a very different regulatory function than the subsequent cortisol awakening response (CAR) [90].
Comparisons between these two indices, in the context of insomnia, are, therefore, difficult to interpret.
The overarching point is that our measures of hyperarousal must be theoretically derived. It is not
enough to implicate a biological system in the pathophysiology of insomnia and then measure its
association using established methods, but without consideration to whether those methods are
consistent with theory (e.g., there’s minimal conceptual rationale for observing group differences in
CAR among patients with CI) [74,91].
All this said, a conservative reading of the behavioral models of insomnia suggest that acute
hyperarousal is sufficient to precipitate acute insomnia but that chronic hyperarousal is not sufficient
to serve as a perpetuating factor for chronic insomnia. The behavioral models (i.e., the 3P and
4P renditions) suggest that chronic insomnia occurs largely in association with behavioral factors
(e.g., sleep extension or being awake for extended periods of time in the bed and bedroom) and
that with time insomnia occurs as “conditioned” wakefulness. Thus, it may be the case that AI is
precipitated by hyperarousal and that CI is perpetuated, to some extent by tonic activation of the
fight/flight system, but in larger measure by conditioned wakefulness and/or the failure to inhibit
wakefulness [92]. If true, it would be expected that AI would show dramatic elevations on measures of
sympathetic activation, while CI would only show modest elevations as compared to what is typical of
good sleep.
Conditioned wakefulness is related to poor stimulus control, or the act of engaging in nonsleep-related
behaviors in bed (or the bedroom) or being awake while in bed for extended periods of time. These behaviors
result in conditioned wakefulness, which refers to the notion that the induction of the physiology of wakefulness,
for example, during the anticipation of sleep, is due to an environmental precipitant. An environmentally
conditioned stimulus (CS) produces the conditioned response (CR) of insomnia [93,94]. This CR may also occur
during sleep, which may explain why individuals with insomnia are quicker to wake up (i.e., the latency to
transition out of the physiological state of sleep may be shorter) and experience more prolonged awakenings
during the night (i.e., the probability of a brief interruption in sleep to lead to a full-blown awakening is greater).
It is possible that there may be a role for hyperarousal here, in that the environmental CS may elicit a conditioned
(physiological) stress response (e.g., an acute increase in HPA/adrenergic hormones or pulse) and that this may in
turn elicit conditioned wakefulness. It is important, however, to distinguish this from a true fear response, in that
this “stress response” is likely not at that level but only incrementally higher than baseline (normal), but enough
to elicit wakefulness. Given some perspectives that insomnia is characterized by a hybrid brain state (localized
wakefulness during otherwise global sleep) [95,96], it may also be the case that these psychobiological responses
are producing localized wakefulness, which may contribute to the high prevalence of sleep-state misperception in
patients with insomnia, or the phenomenon that an individual perceives oneself to be awake (retrospectively),
despite being classified (polysomnographically) as being asleep. This said, rather than “hyperarousal”, CI may
be better characterized by disinhibition of wakefulness or a failure to inhibit wakefulness during times of sleep
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or a disconnect between systems that are supposed to be online/offline during wake/sleep (i.e., maladaptive
conditioning) [92,95].
7. Where to from Here?
The goal of the present theoretical review is three-fold: (1) To provide a clear definition for acute
and chronic insomnia, based on the available nosological manuals and the scientific literature, with a
special emphasis on the limitations of these definitions; (2) to provide a clear definition for hyperarousal,
as it relates to insomnia; and (3) to proffer the perspective that the two beliefs described at the opening
of this paper are not necessarily true, or at least, that the relationship between acute and chronic
insomnia (and hyperarousal) is more complex than previously believed. This alternative perspective
suggests that AI and CI are not necessarily different points in the natural history of insomnia (disorder),
but rather that they are distinct states. More, there is no clear evidence to support that the severity and
frequency of AI and CI are the same (it may be the case that AI is a brief yet more intense version of CI)
and/or that the biopsychosocial concomitants of AI and CI are the same. While the symptom profiles
for the two are the same (at least from a theoretical perspective), the etiology and pathophysiology of
each are likely very different, and specifically AI may be more about “hyperarousal”, whereas CI may
be more related to other processes, such as homeostatic dysregulation and/or conditioned wakefulness.
It is possible that these processes are related to traditional indices of hyperarousal. However, we argue
here that the use of the term “hyperarousal” may be a misrepresentation of the magnitude of these
responses and that the hyperarousal observed in CI may be different than the hyperarousal observed
in AI, and importantly, that these two should not be conflated.
Based on the current state of the science, the following recommendations are offered, with the
intention that they could potentially guide future research efforts:
(1) Natural history of insomnia data should be used to define what constitutes the temporal stages
of insomnia. Note: It seems likely that such data will need to capture normal variation in sleep
continuity, acute sleeplessness, persistent poor sleep, and chronic insomnia (e.g., Insomnia Disorder).
(2) The temporal stages of insomnia should be compared regarding incident frequency and severity
(i.e., does sleep continuity disturbance occur on more days per week and/or with greater average
severity when the insomnia is normative vs. acute vs. persistent vs. chronic?).
(3) Multi-method, multi-trait type studies of insomnia should be used to define when “acute
hyperarousal” (fight-or-fight responding) is and is not solely responsible for the occurrence of
difficulties initiating and maintaining sleep.
(4) Experimental assays or protocols should be developed to distinguish between sleeplessness
due to hyperarousal and insomnia due to conditioned wakefulness and/or the failure to
inhibit wakefulness.
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